Older Males Using Opioids, With Muscle Disease, at Higher Risk for Pseudo-obstructions, Study Reports

Older Males Using Opioids, With Muscle Disease, at Higher Risk for Pseudo-obstructions, Study Reports
This post was originally published on this site

pseudo-obstruction

Being older, male, using opioids, having the diffuse cutaneous disease type, and muscle disease, increase the risk of pseudo-obstruction in people with systemic sclerosis (SSc), a study shows.

The research, “Evaluation of risk factors for pseudo-obstruction in systemic sclerosis,” was published in the journal Seminars in Arthritis and Rheumatism.

Pseudo-obstruction, a condition with similar symptoms to those of intestinal obstruction but with no physical blockage detected in exams, is a rare but severe complication in people with SSc. However, its risk factors in this patient population are still poorly defined.

Aiming to address this gap, a team at Johns Hopkins University analyzed patients treated at the Johns Hopkins Scleroderma Center between February 2003 and September 2017. To be classified as having pseudo-obstruction, individuals had to have a modified Medsger gastrointestinal (GI) severity score of 3. They also had to present at least three of the following features: abdominal pain, nausea, vomiting, failure to pass gas, bloating, distention, or high-pitched bowel sounds. Alternative causes of obstruction were ruled out based on imaging and physician notes.

Among a total 2,812 SSc patients, 175 (22.9%) had a history of pseudo-obstruction. Their mean age at first symptoms was 44.1 years, and the median disease duration from first symptoms to baseline visit was 5.0 years. The follow-up interval was 3.5 years.

Compared with people without pseudo-obstruction, those with this complication were significantly more likely to be male (23% vs. 15%), have diffuse cutaneous disease (48% vs. 36%), and cardiac involvement (44% vs. 26%). These individuals also were more like to have myopathy, or muscle disease (29% vs. 15%), severe Raynaud’s syndrome (66% vs. 53%), and elevated right ventricular systolic pressure (43 vs. 37 mmHg).

SSc patients with pseudo-obstruction also reported a greater use of opioids (43% vs. 26%) or prokinetics — medicines to improve the motility of the GI tract (63% vs. 16%). They also reported  greater use of antibodies against U3RNP, or fibrillarin (7% vs. 3%), and were more likely to die (44% vs. 24%).

Conversely, patients with pseudo-obstruction were less likely to have antibodies against RNA polymerase III, a marker of SSC disease (11% vs. 19%), than those without.

A subsequent analysis confirmed that older age, longer time having the disease, being male, opioid use, and having diffuse cutaneous disease, myopathy, and cardiac involvement, all were significantly associated with pseudo-obstruction in SSc patients. The team further reported that opioid use could be a modifiable risk factor for pseudo-obstruction.

“These clinical features may allow for earlier diagnostic evaluation and/or therapeutic intervention for patients at risk for pseudo-obstruction,” the researchers said.

In particular, “opioid usage should be further evaluated in prospective studies to better understand its role as a modifiable risk factor, and explore how opioid indication, formulation, dosing, timing, and cessation affect the development of pseudo-obstruction,” they added.

The post Older Males Using Opioids, With Muscle Disease, at Higher Risk for Pseudo-obstructions, Study Reports appeared first on Scleroderma News.

Chris Comish serves as the Publisher of the website, and is responsible for directing the editorial focus as well as putting the finishing touches on many featured articles.